The phase II Nabrax GEICAM study of neoadjuvant nab-paclitaxel 150 mg/m2 the first 3 of 4 weeks (qw 3/4) in patients with ER-positive, HER2-negative breast cancer demonstrated an ORR of 76.5% [13]. This evidence concerns the gene ERBB2 and breast cancer.